Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REIMAGINE 2: CagriSema versus semaglutide, cagrilintide, and placebo in adults with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor
CTR20240080Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of CagriSema, semaglutide, cagrilintide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Jan 2024; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20240080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240080.